Mass. General Hospital has joined a World Heart Corp.’s (NSDQ:WHRT) heart pump study.
The Boston-based hospital will take part in the circulatory support system maker’s bridge-to-transplant clinical study of its Levacor ventricular assist device.
MGH, Louisville, Ky.-based University of Louisville/Jewish Hospital and Tampa, Fla.-based Tampa General Hospital joined three other hospitals in the study.
The Salt Lake City, Utah-based company said its Levacor VAD "is the only fully magnetically levitated, bearingless, implantable centrifugal pump to move into clinical trial." The company designed the device’s magnetically levitated rotor to eliminate wear and increase the ranges of blood flow.